The fifth set of standard enterprises of science and Technology Innovation Board announced feedback and reply, taking a big step in the review progress

[pharmaceutical network industry trends] more than a month has passed since the opening of science and technology innovation board on July 22 According to statistics, as of August 13, 151 science and technology innovation board enterprises have been accepted It is worth mentioning that among these 151 enterprises, there are some unprofitable enterprises, which is also the difference between the A-share market before the advent of science and technology innovation board, breaking the past evaluation system based on profitability In addition, science and innovation enterprises represented by innovative drug R & D enterprises are highly concerned The fifth set of listing standards of science and technology innovation board is considered to be specially for unprofitable biomedical enterprises, that is, "the market value is expected to be no less than 4 billion yuan, the main business or products need to be approved by the relevant departments of the state, the market space is large, and the phased results have been achieved at present Pharmaceutical enterprises shall have at least one core product approved to carry out phase II clinical trials, and other enterprises in line with the positioning of scientific and Technological Innovation Board shall have obvious technical advantages and meet the corresponding conditions " According to the author's review, at present, there are three unprofitable innovative drug companies landing on the science and technology innovation board with the help of the fifth set of listing standards, and one has published a round of feedback reply Zejing pharmaceutical: it has announced the feedback reply to Zejing pharmaceutical, which was accepted on June 10, and plans to raise 2.384 billion yuan According to the financial data, the company's operating revenue from 2016 to 2018 is 200000 yuan, 0 yuan and 1311200 yuan, and the net profit attributable to the parent company is - 128 million yuan, - 146 million yuan and - 440 million yuan It can be seen that the company has been in a state of loss in recent years Zejing pharmaceutical issued a circular reply to the Shanghai Stock Exchange inquiry on July 31, but only recently published the feedback reply From the public information, the Shanghai Stock Exchange raised 10 questions in this round of reply, involving clear equity, identification of the actual controller, related party transactions, share based payment, etc According to Zejing pharmaceutical prospectus, the company is a new drug R & D enterprise focusing on the treatment of tumor, bleeding and blood diseases, hepatobiliary diseases and other diseases At present, the company's product pipeline includes 23 research projects of 11 innovative drugs Baiaotai: none of the products are sold on the market Baiaotai is the second enterprise to choose the fifth set of standards on the science and technology innovation board, which was accepted on July 8 The net losses of the company in 2016, 2017 and 2018 were 136584100 yuan, 235559500 yuan and 553111200 yuan respectively It can be seen that the company has also been in a state of loss According to the prospectus, baiaotai is an innovative biopharmaceutical enterprise focusing on the research and development of innovative drugs and bio similar drugs As of the signing date of the prospectus, there are 21 products under development, one of which has submitted the application for listing, and other products are in the stage of clinical research As the product is not sold on the market, no revenue is generated Frontier biology: only one product was launched on August 13 According to the Shanghai Stock Exchange, frontier biology's application for listing on science and technology innovation board was accepted According to the prospectus, frontier biology is an innovative biomedical enterprise focusing on the research, development, production and sales of new drugs in the field of long-acting peptides The company is still in the unprofitable stage From 2016 to 2018, its attributable net profits are about - 23.4767 million yuan, - 65.2799 million yuan and - 247 million yuan respectively As of March 31, 2019, the company's accumulated outstanding loss is 428 million yuan It is also disclosed that during the reporting period, there was a product on sale in frontier biology, and the revenue mainly came from the sale of the original new drug iconine The industry believes that innovative drug R & D is a high investment and high-risk business At present, there is only one product listed in the company, and the future product sales are also uncertain The company says that after the successful listing of new drug R & D, it will bring very considerable profits.